Asset profile
AZD8233
RNA / oligonucleotide
Evidence outlook · program status
Discontinued (2022), as a strategic decision by the sponsor
AZD8233 was AstraZeneca's subcutaneous PCSK9 antisense oligonucleotide for hypercholesterolaemia/ASCVD risk. The terminated renal-impairment study NCT05065463 states in its own record that AstraZeneca decided to discontinue development of AZD8233 because it was unlikely to beat standard of care. The trial stopped 2022-11-23 and the record was verified 2022-12. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 18 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 70 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD8233: this drug | Phase 2 | RNA / oligonucleotide | PCSK9 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| AZD0780 | Phase 3 | Small molecule | PCSK9 | ||
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| Enlicitide | Phase 3 | Peptide | PCSK9 | ||
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | ||
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | ||
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| SYH2053 | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| Tafolecimab (Sintbilo) | Phase 3 | Monoclonal antibody | PCSK9 | ||
| DNV001 | Phase 2 | Monoclonal antibody | PCSK9 | ||
| HRS-1301 | Phase 2 | Small molecule | PCSK9 | ||
| COR-1004 | Phase 1 | — | PCSK9 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
12 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.